Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma
Pilot Study to Evaluate the Safety, Tolerability and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma (Phase I)
Sponsor: Center Trials & Treatment Europe
A PHASE1 clinical study on Astrocytoma of Brain and Glioma, Malignant, this trial is completed. The trial is conducted by Center Trials & Treatment Europe and has accumulated 7 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
May 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Unknown Status → Completed
-
Oct 2021 — May 2023 [monthly]
Unknown Status PHASE1
Status: Not Yet Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE1
-
Oct 2019 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Center Trials & Treatment Europe
For direct contact, visit the study record on ClinicalTrials.gov .